ADA and autoimmune disease: The similar dynamic of ADA production across different BPs, the high immunogenicity of BPs when given to patients with autoimmune disease, and the immune hyperresponsiveness characteristic of these diseases suggest that ADA development may share common immunogenetic pathways.